Illumina, Inc. $ILMN Shares Sold by Mitsubishi UFJ Trust & Banking Corp

Mitsubishi UFJ Trust & Banking Corp decreased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 3.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 193,230 shares of the life sciences company’s stock after selling 6,912 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned 0.13% of Illumina worth $18,351,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Envestnet Portfolio Solutions Inc. boosted its holdings in shares of Illumina by 0.8% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 12,074 shares of the life sciences company’s stock worth $1,152,000 after purchasing an additional 99 shares during the last quarter. Versant Capital Management Inc lifted its position in Illumina by 8.9% during the third quarter. Versant Capital Management Inc now owns 1,364 shares of the life sciences company’s stock worth $130,000 after buying an additional 111 shares during the period. Parkside Financial Bank & Trust boosted its stake in Illumina by 65.7% in the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after buying an additional 115 shares during the last quarter. Bouvel Investment Partners LLC boosted its stake in Illumina by 2.3% in the 3rd quarter. Bouvel Investment Partners LLC now owns 6,129 shares of the life sciences company’s stock worth $582,000 after buying an additional 136 shares during the last quarter. Finally, Arkadios Wealth Advisors grew its holdings in Illumina by 1.7% in the 2nd quarter. Arkadios Wealth Advisors now owns 9,130 shares of the life sciences company’s stock valued at $871,000 after buying an additional 157 shares during the period. 89.42% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on ILMN shares. Canaccord Genuity Group increased their price objective on shares of Illumina from $130.00 to $150.00 and gave the stock a “hold” rating in a report on Monday. UBS Group upped their price target on shares of Illumina from $110.00 to $120.00 and gave the stock a “neutral” rating in a research report on Friday, October 31st. Robert W. Baird set a $109.00 price target on shares of Illumina in a report on Friday, October 31st. Zacks Research downgraded Illumina from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 31st. Finally, Wall Street Zen raised Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. Six research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Illumina currently has a consensus rating of “Hold” and a consensus target price of $127.18.

Insiders Place Their Bets

In related news, insider Scott M. Davies sold 323 shares of Illumina stock in a transaction on Friday, December 12th. The shares were sold at an average price of $136.09, for a total transaction of $43,957.07. Following the sale, the insider owned 17,887 shares of the company’s stock, valued at $2,434,241.83. The trade was a 1.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Scott Gottlieb acquired 500 shares of the business’s stock in a transaction on Monday, November 3rd. The stock was purchased at an average price of $122.13 per share, for a total transaction of $61,065.00. Following the acquisition, the director directly owned 12,523 shares in the company, valued at $1,529,433.99. This represents a 4.16% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 0.17% of the company’s stock.

Illumina Stock Up 1.8%

Shares of Illumina stock opened at $153.00 on Tuesday. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $155.53. The stock has a market cap of $23.38 billion, a price-to-earnings ratio of 34.30, a price-to-earnings-growth ratio of 2.49 and a beta of 1.41. The company has a current ratio of 1.43, a quick ratio of 1.12 and a debt-to-equity ratio of 0.42. The company has a fifty day moving average price of $135.86 and a 200 day moving average price of $113.72.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.16 by $0.18. Illumina had a return on equity of 29.21% and a net margin of 16.40%.The company had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same period last year, the company posted $1.14 earnings per share. The firm’s revenue was up .4% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Equities research analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.